

## **Product datasheet for TA365237S**

## **UBXN2B Rabbit Polyclonal Antibody**

## **Product data:**

**Product Type:** Primary Antibodies

Applications: IHC

Recommended Dilution: IHC: 25-100

Positive control: Human gastric cancer

Predicted cell location: Nucleus

Reactivity: Human, Mouse, Rat

Host: Rabbit Isotype: IgG

Clonality: Polyclonal

**Immunogen:** Fusion protein of human UBXN2B

**Formulation:** pH7.4 PBS, 0.05% NaN3, 40% Glycerol

**Purification:** Antigen affinity purification

Conjugation: Unconjugated Storage: Store at -20°C.

Stability: 1 year

**Gene Name:** UBX domain protein 2B

**Database Link:** Entrez Gene 137886 Human

Q14CS0

Background: UBXD2B (UBX domain-containing protein 2B), also known as NSFL1 cofactor p37 and p97

cofactor p37, is a 331 amino acid protein that contains one UBX domain and one SEP domain. UBXN2B is required for ER and Golgi biogenesis and also plays a role in their maintenance during interphase, as well as their reassembly at the end of mitosis. Through interaction with VCP, UBXN2B forms a complex that has membrane fusion activity. Adapter protein required for Golgi and endoplasmic reticulum biogenesis. Involved in Golgi and endoplasmic reticulum maintenance during interphase and in their reassembly at the end of mitosis. The complex formed with VCP has membrane fusion activity; membrane fusion activity requires USO1-GOLGA2 tethering and BET1L. VCPIP1 is also required, but not its

deubiquitinating activity.



**OriGene Technologies, Inc.** 9620 Medical Center Drive, Ste 200


CN: techsupport@origene.cn

Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com




**Synonyms:** p37

## **Product images:**



Immunohistochemistry of paraffin-embedded Human gastric cancer tissue using [TA365237] (UBXN2B Antibody) at dilution 1/35 (Original magnification: ×200)



Immunohistochemistry of paraffin-embedded Human gastric cancer tissue using [TA365237] (UBXN2B Antibody) at dilution 1/35, treated with fusion protein. (Original magnification: ×200)